The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

- Substantially pure DNA or RNA consisting essentially of nucleotide sequence corresponding to the Apa I restriction fragment of a human erythropoietin gene.
- The DNA or RNA of Claim 1 wherein the Apa I restriction fragment consists essentially of the nucleotide sequence of either the sense strand shown in FIGURE 1 or the complementary RNA sequence thereof.
- 3. The DNA or RNA sequence of Claim 1 operably linked to a second nucleic acid sequence capable of effecting expression thereof.
- 4. The DNA or RNA of Claim 3 wherein the second nucleic acid sequence is selected from one or more of the following: promoter sequences, enhancer sequences, polyadenylation sequences, selectable marker sequences, plasmids, viral and retroviral expression vectors, and retroviral trans-acting factors.
 - 5. Cells containing the DNA or RNA of Claim 3.
 - 6. Cells stably transfected with the DNA or RNA of Claim 3.
- 7. Celis of Claim 6 selected from the group consisting of eukaryotic cells, yeast, and bacteria.
- Cells of Claim 7 wherein the eukaryotic cells are of kidney origin.
- $\mbox{9.} \qquad \mbox{Cells of Claim 8 wherein the kidney cells are epithelial} \label{eq:cells}$ cells.

5

5

5

- 10. A method of expressing recombinant biologically active human erythropoietin comprising the steps of transfecting a host cell line with DNA, RNA, or nucleotide sequence consisting essentially of the Apa l restriction fragment of a human erythropoietin gene, contacting the transfected cells with culture medium to permit the cells to express erythropoietin, and recovering the expressed erythropoietin.
- 11. The method of Claim 10 wherein the Apa I restriction fragment is carried on a plasmid or virus.
- 12. The method of Claim 10 wherein the host cell line is selected from the group consisting of eukaryotic cells, yeast, and bacteria.
- 13. In a method of expressing recombinant biologically active human erythropoietin from a cell line in contact with an incubating medium, the improvement which comprises incorporating in said method a cell line capable of permitting a yield of erythropoietin in the incubating medium, said cell line having been produced by transfecting a host cell line with DNA, RNA, or nucleotide sequence consisting essentially of the Apa I restriction fragment of a human erythropoietin gene.
- 14. The method of expressing recombinant biologically active human erythropoietin from a cell line in contact with an incubating medium in accordance with Claim 13, wherein said cell line is capable of permitting a nominal yield of at least two million Units of erythropoietin per liter of incubating medium.
- $$15$. \ \ \,$ The method of Claim 13 wherein said Apa I restriction fragment is carried on a plasmid.
- $16.\ \$ The method of Claim 13 wherein said Apa I restriction fragment is carried on a virus.
- 17. The method of Claim 13 wherein the host cell line is selected from the group consisting of eukaryotic cells, yeast, and bacteria.

